Authors
Latest:
Dr. Collins on the Rationale for CDK4/6 Inhibitors in ER+ Breast CancerJulie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.
Latest:
Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid SyndromeDrs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
Latest:
Dr Hansford on the FIREFLY-1 Trial of Tovorafenib in Pediatric Low-Grade GliomaJordan Hansford, MD, discusses the phase 2 FIREFLY-1 trial, which is investigating the pan-RAF inhibitor tovorafenib (DAY101) in children and young adults with low-grade glioma.
Latest:
Dr. Nagle on Investigational Cellular Therapies in Multiple MyelomaSarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.
Latest:
Dr. Robinson on the Updated Results of the KEYNOTE-407 Trial in Squamous NSCLCAndrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.
Latest:
Dr. Vorobiof on the Impact of Financial Toxicity in the Field of OncologyDaniel A. Vorobiof, MD, the chief medical director of Belong.Life, discusses the impact of financial toxicity on patients with cancer.
Latest:
Dr. Ghia on the Key Takeaways of the CAPTIVATE Study in Treatment-Naïve CLLPaolo Ghia, MD, PhD, discusses the key takeaways of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia.
Latest:
Neighborhood Plays an Important Role in Clinical Outcomes for Patients With Breast CancerAddressing socioeconomic health disparities has been a crucial objective of health policy in the United States. The relationship between cancer incidence and mortality and socioeconomic status varies across malignancies.
Latest:
Dr. Hecht on the Investigation of XL092/Atezolizumab in MSS/MSI-L mCRCJ. Randolph (Randy) Hecht, MD, discusses the investigation of XL092 plus atezolizumab in patients with microsatellite stable/microsatellite instability–low metastatic colorectal cancer.
Latest:
Dr. Ko on Unmet Needs in PD-L1–Negative TNBCHeidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.
Latest:
Dr. Dhakal on the Evolution of Pertuzumab Regimens in HER2+ Breast CancerAjay Dhakal, MBBS, discusses the two key trials supporting the use of pertuzumab as a standard-of-care regimen in HER2-positive breast cancer.
Latest:
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and TreatmentLearn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.
Latest:
Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast CancerSenthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.
Latest:
Final Thoughts on New Developments and Emerging AgentsPanelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
Latest:
Dr Siegel on the Use of Carfilzomib/Iberdomide/Dexamethasone Therapy in Multiple MyelomaDavid Samuel Dicapua Siegel, MD, discusses the potential use of carfilzomib, iberdomide, and dexamethasone in newly diagnosed multiple myeloma.
Latest:
Investigators Seek to Resolve the “Obesity Paradox” in Lung CancerSmoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.
Latest:
Dr O’Brien on Advances in Molecular Imaging in ER+ Breast CancerSophia R. O'Brien, MD, discusses recent advances in the diagnosis and staging of estrogen receptor–positive metastatic breast cancer.
Latest:
Dr Reshef on Data From the BMT CTN 1703 Trial Evaluating Post-Transplant GVHD Prophylactic RegimensRan Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.
Latest:
Future Perspectives on the Treatment Landscape for CLLA panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.
Latest:
Dr Gopal on Treatment Selection in Second-Line R/R mUCNikhil A. Gopal, MD, discusses treatment selection in second-line relapsed/ refractory metastatic urothelial cancer.
Latest:
Dr. Kim on Clinical Implications of ADCs in HER2+ Solid TumorsEdward S. Kim, MD, MBA, discusses the clinical implications of antibody-drug conjugates in HER2-positive solid tumors.
Latest:
Dr. Schenk on the Importance of Investigating Novel Targets in Lung CancerErin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.
Latest:
$10.8M Initiative Unites Engineering and Health Researchers to Improve Cancer TreatmentsA University of Arizona project, with funding from the state's New Economy Initiative, creates humanlike cancer models and growth environments to help improve prevention, diagnosis and treatment.
Latest:
Freeman on Mortality Differences Across Racial Groups in Male Patients With Breast CancerJason Jincong Freeman, discusses mortality differences across various racial groups in male patients with stage I, II, or III breast cancer.
Latest:
Dr. Puechl on Choosing Between PARP Inhibitors in Ovarian CancerAllison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.
Latest:
Dr Hafez on the Influence of Biomarker Expression on Adjuvant T-DM1 Use in HER2+ Breast CancerMaria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.
Latest:
Dr. Pianko on the Role of Daratumumab in Frontline MyelomaMatthew James Pianko, MD, discusses the role of daratumumab in the frontline treatment of multiple myeloma.
Latest:
Dr Sammons on the Investigation of Brain Metastases in HER2+ Breast CancerSarah Sammons, MD, discusses the rationale for examining brain metastases in HER2-positive breast cancer, highlighting the implications of recent data.
Latest:
Future Directions With PSMA Ligand–Directed TherapiesHighlights of potential future applications of PSMA ligand–directed therapies in prostate cancer.
